Chronic inflammatory liver disease: cell stress mechanisms identified as prognostic factor: PSC is a rare disease with a poor prognosis and can lead to cirrhosis of the liver or bile duct cancer. It affects 0.01% of the population but, even though it is rare, PSC is responsible for more than 10% of all liver transplants, making it the third most common indication on liver transplant waiting lists in Europe.
In the recent study, which has now been published in the leading journal “Hepatology”, the researchers were able to identify a molecular signature for ER stress both in the liver cells (hepatocytes) and also in the bile duct epithelium – and notably as a stand-alone factor that is independent of the disease stage or degree of liver fibrosis (laying down of scar tissue) as a precursor to possible liver cirrhosis. “Using transcriptional analysis, we were able to identify a personalised molecular signature of primary sclerosing cholangitis, which shows that patients with an impaired response to ER stress have a poorer prognosis with a higher incidence of complications,” explains Trauner. “This discovery also opens up new treatment options, since ER stress can be counteracted with drugs.”
Since the build-up of potentially toxic bile acids in cholestasis results in ER stress, it is now being attempted to restore this balance pharmacologically using the new bile acid therapeutics that are available. Beneficial effects can reportedly be expected from drugs already in clinically testing – however, more research has already been initiated to explore this further.
MedUni Vienna a world-leading hepatology centre
The international study was conducted under the lead of of MedUni Vienna, working with teams from the USA (Fairfax Hospital; Feinberg School of Medicine, Chicago; University of Miami; Liver Institute Northwest, Seattle; University of California at Davis, Sacramento; Duke University School of Medicine, Durham) and Canada (University of Alberta, Edmonton) in collaboration with Gilead Sciences and the biopsies were enabled by a clinical trial conducted by Gilead. MedUni Vienna’s Division of Gastroenterology and Hepatology is regarded as one of the world’s leading centres for research into primary sclerosing cholangitis (PSC), non-alcoholic fatty liver disease (NAFLD) and bile acid metabolism disorders in liver and biliary tract disease. Currently, one of MedUni Vienna’s main research interests in the Immunology Research Cluster is immunometabolism, which is concerned with the interaction between immunologic and metabolic processes.
Service: Hepatology
“A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis.” Yevgeniy Gindin, Chuhan Chung, Zhaoshi Jiang, Jing Zhu Zhou, Jun Xu, Andrew N. Billin, Robert P. Myers, Zachary Goodman, Abdolamir Landi, Michael Houghton, Richard M. Green, Cynthia Levy, Kris V. Kowdley, Christopher L. Bowlus, Andrew J. Muir and Michael Trauner. Link: https://doi.org/10.1002/hep.31488
 logo final copy.png)
- Pilot whole genome sequencing service - 22nd October 2024
- Coping with SAD: A guide for university students - 22nd October 2024
- Plugging into pain: ant toxin causes electrical sting - 18th October 2024
